Five years of ibrutinib in CLL
- PMID: 29794077
- DOI: 10.1182/blood-2018-03-837864
Five years of ibrutinib in CLL
Conflict of interest statement
Conflict-of-interest disclosure: The author declares no competing financial interests.
Comment on
-
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26. Blood. 2018. PMID: 29483101 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources

